What is the price of Cocrystal Pharma stock?
One share of COCP stock can currently be purchased for approximately $0.73. How much money does Cocrystal Pharma make? Cocrystal Pharma has a market capitalization of $70.72 million and generates $2.01 million in revenue each year.
What does COCP stand for?
Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, will present data from its unique structure-based drug design platform...
Who sells cocop stock?
COCP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, HighTower Advisors LLC, and BlackRock Inc.. View insider buying and selling activity for Cocrystal Pharma or view top insider-selling stocks.
Where can I buy shares of COCP?
Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is COCP stock a good buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: COCP) stock is to Strong Buy COCP stock.
Where can I buy COCP stock?
Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Will COCP go up?
Cocrystal Pharma Inc (NASDAQ:COCP) The 2 analysts offering 12-month price forecasts for Cocrystal Pharma Inc have a median target of 4.50, with a high estimate of 5.00 and a low estimate of 4.00. The median estimate represents a +1,016.63% increase from the last price of 0.40.
Who owns COCP stock?
Top 10 Owners of Cocrystal Pharma IncStockholderStakeShares ownedThe Vanguard Group, Inc.3.33%3,246,128Renaissance Technologies LLC1.75%1,704,328BlackRock Fund Advisors1.12%1,093,827Geode Capital Management LLC0.82%800,6026 more rows
What is combined pill made up of?
The combined hormonal contraceptive pill (the Pill) is made up of two hormones, an oestrogen and a progestogen. These hormones are similar to the ones made in your ovaries. Many brands of the Pill are available which all have different types and doses of these two hormones.
How do you take progesterone only pills?
You need to take 1 pill every day within either 3 or 12 hours of the same time each day, depending on which type you're taking. There's no break between packs of pills – when you finish a pack, you start the next one the next day.
Is COCP stock a buy right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are cu...
Will Cocrystal Pharma's stock price go up in 2022?
2 Wall Street analysts have issued 1-year price targets for Cocrystal Pharma's stock. Their forecasts range from $4.00 to $5.00. On average, they a...
How has Cocrystal Pharma's stock performed in 2022?
Cocrystal Pharma's stock was trading at $0.65 at the start of the year. Since then, COCP shares have decreased by 32.4% and is now trading at $0.43...
Are investors shorting Cocrystal Pharma?
Cocrystal Pharma saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 58,200 shares, a decline of...
When is Cocrystal Pharma's next earnings date?
Cocrystal Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Cocr...
How were Cocrystal Pharma's earnings last quarter?
Cocrystal Pharma, Inc. (NASDAQ:COCP) released its earnings results on Wednesday, May, 11th. The company reported ($0.04) EPS for the quarter, meeti...
Who are Cocrystal Pharma's key executives?
Cocrystal Pharma's management team includes the following people: Dr. Roger D. Kornberg Ph.D. , Co-Founder, Chairman, Chief Scientist & Chairman...
Who are some of Cocrystal Pharma's key competitors?
Some companies that are related to Cocrystal Pharma include Alaunos Therapeutics (TCRT) , KemPharm (KMPH) , Savara (SVRA) , Spectrum Pharmaceut...
What other stocks do shareholders of Cocrystal Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA) , H...
Is Cocrystal Pharma stock a Buy, Sell or Hold?
Cocrystal Pharma stock has received a consensus rating of buy. The average rating score is and is based on 2 buy ratings, 0 hold ratings, and 0 sel...
What was the 52-week low for Cocrystal Pharma stock?
The low in the last 52 weeks of Cocrystal Pharma stock was 0.37. According to the current price, Cocrystal Pharma is 110.16% away from the 52-week...
What was the 52-week high for Cocrystal Pharma stock?
The high in the last 52 weeks of Cocrystal Pharma stock was 1.49. According to the current price, Cocrystal Pharma is 27.52% away from the 52-week...
What are analysts forecasts for Cocrystal Pharma stock?
The 2 analysts offering price forecasts for Cocrystal Pharma have a median target of 4.75, with a high estimate of 5.00 and a low estimate of 4.50....
How much does Cocrystal Pharma make?
When will Cocrystal Pharma release its earnings?
How much money does Cocrystal Pharma make? Cocrystal Pharma has a market capitalization of $111.12 million and generates $2.01 million in revenue each year . The company earns $-9,650,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.
Ideas
Cocrystal Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Cocrystal Pharma.
Profile
Weekly chart, beautiful channel, history of volatility. It seems to be respecting lots of trend lines Clear lines of S & R Easy double up imo
News & Analysis: Cocrystal Pharma, Inc
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections.
Environmental, Social, and Governance Rating
There is no available coverage of Cocrystal Pharma, Inc. at this time.
What is CC-31244?
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Does market cap include convertible securities?
It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleo. side inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Key Executives. Name.
Signals & Forecast
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Monday, January 24, 2022, and so far it has risen 11.16%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Cocrystal Pharma Inc stock A Buy?
Cocrystal Pharma Inc finds support from accumulated volume at $0.53 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Cocrystal Pharma Inc
Cocrystal Pharma Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Golden Star Signal
In the last 92 trades there were 453.93 million shares bought and 59.81 million shares sold. The last trade was done 189 days ago by Pfenniger Richard C Jr who bough 40 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is Cocrystal Pharma?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is CC-31244?
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
